Recently, several institutional investors and hedge funds traded shares of G1 Therapeutics. Marathon Trading Investment Management invested $46,000 in the second quarter. XTX Topco Ltd increased its holdings by 104% to 21,020 shares, now worth $48,000 after acquiring 10,718 additional shares. Los Angeles Capital Management also bought shares for about $48,000, while SG Americas Securities invested around $58,000 in the first quarter. Rhumbline Advisers boosted its stake by a massive 5,136%, now holding 50,632 shares valued at $115,000 after adding 49,665 shares. Hedge funds and other institutional investors own 24.21% of the stock.
G1 Therapeutics Stock Performance
On Wednesday, G1 Therapeutics (GTHX) opened at $7.15. The stock has ranged from a low of $1.08 to a high of $7.19 over the past year. Key financial ratios include a current ratio of 2.48 and a debt-to-equity ratio of 1.34. The market cap is $373.81 million with a P/E ratio of -11.53.
G1 Therapeutics reported earnings on August 8, showing a loss of $0.10 per share, which exceeded expectations of a $0.17 loss. The company had revenue of $16.55 million for the quarter, beating the forecast of $15.88 million. Analysts predict a -0.45 EPS for this fiscal year.
Wall Street Analyst Opinions
GTHX has been rated by various analysts. HC Wainwright downgraded it from “strong-buy” to “hold” on August 8. Needham & Company and Wedbush also maintained “hold” ratings on August 7.
About G1 Therapeutics
G1 Therapeutics, Inc. is a biopharmaceutical company that develops therapies for cancer treatment in the U.S. Its product, COSELA, aims to reduce chemotherapy-induced myelosuppression in patients with certain lung cancer treatments.
Recommended Articles
- Five stocks we like better than G1 Therapeutics
- Understanding Energy and Oil Stocks
- NVIDIA’s AI Dominance and Future Predictions
- Three Healthcare Dividend Stocks to Consider
- Stocks Using Buybacks for Investor Gains
- Stock Average Calculator
- Your Entry Point into PepsiCo
Curious about other hedge funds holding GTHX? Check HoldingsChannel.com for the latest filings and trades for G1 Therapeutics (NASDAQ:GTHX).
Get Daily News & Ratings for G1 Therapeutics – Enter your email for a summary of the latest news and analyst ratings for G1 Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
`
